---
title: "Biokin Pharmaceutical T-Bren (HER2 ADC) demonstrates best-in-class potential, revealing efficacy data for treated HER2 mutated NSCLC for the first time, with a 12-month PFS rate of 73.5%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/268856072.md"
description: "Biokin Pharmaceutical disclosed for the first time at the 2025 European Society for Medical Oncology Asia Congress (ESMO-Asia) the efficacy data of its self-developed HER2 ADC drug T-Bren in patients with HER2-mutated advanced treated non-small cell lung cancer (NSCLC), with a 12-month progression-free survival rate of 73.5%, demonstrating best-in-class potential"
datetime: "2025-12-07T10:48:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/268856072.md)
  - [en](https://longbridge.com/en/news/268856072.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/268856072.md)
generator: "portal-rs"
---

# Biokin Pharmaceutical T-Bren (HER2 ADC) demonstrates best-in-class potential, revealing efficacy data for treated HER2 mutated NSCLC for the first time, with a 12-month PFS rate of 73.5%

Biokin Pharmaceutical announced during the oral presentation session at the 2025 European Society for Medical Oncology Asia Congress (ESMO-Asia) the clinical research results of its independently developed flagship product T-Bren (BL-M07D1), a novel HER2 antibody-drug conjugate (HER2 ADC) targeting advanced treated non-small cell lung cancer (NSCLC) with HER2 mutations

### Related Stocks

- [02615.HK](https://longbridge.com/en/quote/02615.HK.md)
- [688506.CN](https://longbridge.com/en/quote/688506.CN.md)

## Related News & Research

- [Buying 30-year bonds? Locking in today's rates could hurt your retirement planning.](https://longbridge.com/en/news/297194547.md)
- [What's Going On With Taiwan Semiconductor Stock Wednesday?](https://longbridge.com/en/news/297022161.md)
- [Fed's Hammack: Low rate era may have been break from norm](https://longbridge.com/en/news/297332684.md)
- [PROXI: Operational improvements and refinancing set the stage for profitability as harvest sizes grow](https://longbridge.com/en/news/297267075.md)
- [TSMC's July Surge Raises the Bar for Nvidia's Foundry](https://longbridge.com/en/news/297079961.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**